Subscribe: Market Wire - Pharmaceuticals and Biotech: Drugs
http://img.marketwire.com/rss/mwPBDR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
cannabis wheaton  cannabis  cfn media  clinical  company  marketwired oct  marketwired october  marketwired  media  new  oct  october 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Drugs

Marketwired - Drugs



Marketwired - Drugs



Last Build Date: Fri, 20 Oct 2017 11:35:57 EDT

Copyright: Copyright: (C) Marketwired
 



ANGLE plc: Notice of AGM

Fri, 20 Oct 2017 11:04:11 EDT

GUILDFORD, SURREY--(Marketwired - Oct 20, 2017) -  ANGLE plc (AIM: AGL) (OTCQX: ANPCY)




Future Farm Builds Vertical Supply Chain with Acquisition -- CFN Media

Fri, 20 Oct 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Oct 20, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing Future Farm Technologies Inc.'s (CSE: FFT) (CNSX: FFT) (FFT.CN) (OTCQB: FFRMF) acquisition of an industrial hemp farm and how it fits into the company's broader cannabis industry strategy.







Reinvigorating Kidney Disease R&D: Latest Innovations Aim to Address Vast Unmet Need -- New Webinar Hosted by Xtalks

Fri, 20 Oct 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - October 20, 2017) - This webinar will examine new and more advanced and personalized precision medicine approaches to kidney disease research, including both potential drugs and technologies. The live broadcast takes place on Friday, November 10, 2017 at 11am EST (4pm GMT), with featured speaker Eric B. Grossman, MD, Vice President and Medical Director of Clinipace Worldwide.




Maricann Provides Update on Financing, NanoLeaf Acquisition and Other Matters

Thu, 19 Oct 2017 23:30:00 EDT

TORONTO, ONTARIO--(Marketwired - Oct. 19, 2017) -




Synthego Receives Intel Capital Investment to Advance CRISPR Bioinformatics

Thu, 19 Oct 2017 14:17:00 EDT

Growth in genomics and genome engineering requires advanced tools for big data




ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx

Thu, 19 Oct 2017 13:57:13 EDT

ViaDerma's Manufacturer has completed the first run of its topical antibiotic being sold as VitaStem by its Sales, Marketing and Distribution Partner Biogenx, Inc.; Distribution will begin as the product is shipped to Distribution points in Florida and Abroad




UPDATE - HempAmericana, Inc. (OTC PINK: HMPQ) Filed its Financial Statements This Week for the Quarter Ending August 31, 2017

Thu, 19 Oct 2017 13:05:58 EDT

NEW YORK, NY--(Marketwired - Oct 19, 2017) - HempAmericana, Inc. (OTC PINK: HMPQ) filed its financial statements this week for the quarter ending August 31, 2017. The company achieved many milestones during the quarter. It raised $320,000 from its Regulation A offering, placed a down payment on a 200-liter extraction machine (lease to own), and formed Hempwerk, Inc., the conduit for its Maine operations. Subsequent to the quarter's end, HMPQ raised an additional $200,000 from the Regulation A offering. As the company continues to seek expansion, it is still actively courting investors for its Regulation A offering, set to expire at the end of March 2018. The company also recently visited a pilot hemp farm in Goshen, NY as it hopes to eventually set up operations in New York State and is actively exploring opportunities for industrial hemp production and products.




HempAmericana, Inc. (OTC PINK: HMPQ) Filed its Financial Statements This Week for the Quarter Ending August 31, 2017

Thu, 19 Oct 2017 11:16:55 EDT

NEW YORK, NY--(Marketwired - Oct 19, 2017) - HempAmericana, Inc. (OTC PINK: HMPQ) filed its financial statements this week for the quarter ending August 31, 2017. The company achieved many milestones during the quarter. It raised $320,000 from its Regulation A offering, placed a down payment on a 200-liter extraction machine (lease to own), and formed Hempwerk, Inc., the conduit for its Maine operations. Subsequent to the quarter's end, HMPQ raised an additional $200,000 from the Regulation A offering. As the company continues to seek expansion, it is still actively courting investors for its Regulation A offering, set to expire at the end of March 2018. The company also recently visited a pilot hemp farm in Goshen, NY as it hopes to eventually set up operations in New York State and is actively exploring opportunities for industrial hemp production and products.




WeedMD Announces $15 Million Bought Deal Private Placement of Convertible Debentures

Thu, 19 Oct 2017 10:37:06 EDT

TORONTO, ONTARIO--(Marketwired - Oct. 19, 2017) -




Rennova Health's Big South Fork Medical Center Is Granted Three Year Certificate of Accreditation by CMS

Thu, 19 Oct 2017 09:20:00 EDT

WEST PALM BEACH, FL--(Marketwired - October 19, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces that Big South Fork Medical Center, has been found to comply with the requirements of the NIAHO Hospital Accreditation Program, and has been awarded full accreditation for a three year term effective as of October 11, 2017.




Dewmar Invests in Opportunities within $2.2 Trillion Entertainment Industry, Plus Exclusive CEO Interview -- CFN Media

Thu, 19 Oct 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Oct 19, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Dewmar International BMC Inc.'s (OTC PINK: DEWM) investments in cannabis-related entertainment projects. CFN Media also interviews the company's CEO, Dr. Marco Moran, about the company's variety of business initiatives in the cannabis, hemp, health, consumer products and entertainment industries.




mCig to Spin-Off Technology Division as a Stand-Alone Public Company

Thu, 19 Oct 2017 08:30:00 EDT

LAS VEGAS, NV--(Marketwired - Oct 19, 2017) - mCig, Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis markets, announced today that the company will spin-off its technology division as a stand-alone public company. In conjunction with the spin-off, mCig shareholders will be awarded shares in the proposed public entity based on their holdings in MCIG. mCig Inc. expects to file the appropriate documents with the SEC within the next 45 days. 




ICC International Cannabis Corporation Announces Presales Agreement to Export an Estimated 120,000 Bottles of CBD Oil to Mexico

Thu, 19 Oct 2017 08:21:46 EDT

Highlights:

- ICC enters into its first CBD sales agreement in Mexico.

- ICC expects 2018 production of 1.2 million 30 millilitre bottles of CBD oil.

- ICC launches new branded CBD oil product - 'BIDIOL'.




Tetra Bio-Pharma Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

Thu, 19 Oct 2017 08:00:00 EDT

OTTAWA, ONTARIO--(Marketwired - Oct. 19, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).




CannaRoyalty Announces Official California Launch of CR Brands Portfolio Through River Collective

Thu, 19 Oct 2017 08:00:00 EDT

Debuts premium suite of cannabis products ahead of full recreational legalization in largest cannabis market in the world




Propanc Biopharma Publishes Key Scientific Data in Peer Reviewed Journal

Thu, 19 Oct 2017 07:49:17 EDT

Pancreatic Proenzymes Provides For Potent Anti-Tumor Efficacy in Pancreatic and Ovarian Cancers




Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis

Thu, 19 Oct 2017 07:30:00 EDT

NORWOOD, MA--(Marketwired - October 19, 2017) -




BioCorRx to Exhibit at the International Association of Chiefs of Police 2017 Annual Conference in Philadelphia

Thu, 19 Oct 2017 07:30:00 EDT

ANAHEIM, CA--(Marketwired - Oct 19, 2017) - BioCorRx, Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will have an exhibit at the International Association of Chiefs of Police (IACP) 2017 Annual Conference at the Pennsylvania Convention Center in Philadelphia, Pennsylvania on October 21-24th.




Preparing for Phase II: Finding the Right Dose, Schedule, and Combination from your Phase I/II Oncology Clinical Trial, New Webinar Hosted by Xtalks

Thu, 19 Oct 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - October 19, 2017) - In a complimentary webinar, experts from Premier Research Paul Hallenbeck, Ph.D., Executive Director of Strategic Development, Oncology, Peter Larson, M.D., Senior Medical Director of Hematology-Oncology and Gabriele Accetta, Principal Biostatistician discuss important factors for planning and executing early-phase oncology clinical trials in preparation for a decision-making Phase II trial. The live event takes place on Tuesday, November 7, 2017 at 11am EST (4pm GMT).




Vitality Biopharma Announces Positive Results for Multiple Cannabinoid Drug Formulations in Treatment of IBD

Thu, 19 Oct 2017 07:00:00 EDT

Proprietary cannabinoid drug formulations have now been shown to effectively treat preclinical models of Crohn's disease and ulcerative colitis




Forbes Magazine Lists HempLife Today Among the Top Five Hemp CBD Companies in Gross Annual Product Sales, Believes industry could hit one billion per year within three years

Thu, 19 Oct 2017 07:00:00 EDT

DENVER, CO--(Marketwired - Oct 19, 2017) - Ubiquitech Software Corp. (OTC PINK: UBQU), through its operating subsidiary HempLifeToday.com, is proud to announce that Forbes Magazine has listed HempLife TodayT among the top five Hemp CBD Companies in gross annual product sales, and that sales of CBD products could hit one billion per year within the next three years. This article was published on August 23rd, 2017; however, the Company chose to wait until 3rd quarter financials were published before bringing this positive article to greater attention.




Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy

Thu, 19 Oct 2017 06:30:00 EDT

Dynavax Expands its TLR9 Agonist Platform in Combination with Anti-PD-1 Therapy to a Third Tumor Type




Advantis Corp. Finalizes Oregon Contract, Accepts Bitcoin From Some New Customers

Wed, 18 Oct 2017 09:20:00 EDT

NEWPORT BEACH, CA--(Marketwired - Oct 18, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) finalized the deal with a private cannabis grower in Oregon to supply Amster-Can canning and branding services. Advantis is shipping the original canning equipment to Oregon to fulfill orders at full production capacity. As Advantis grows its client base, it has decided to accept Bitcoin as payment from clients that prefer this mode of payment.




Tetra Bio-Pharma Signs Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

Wed, 18 Oct 2017 08:00:00 EDT

OTTAWA, ONTARIO--(Marketwired - Oct. 18, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR). Tetra has signed a distribution agreement with its trusted partner Aphria to sell Rx PrincepsT, its unique blend of dried medical cannabis used in its PPP0001 clinical trials. Production of Rx Princeps has been initiated and will be available to patients in the coming weeks.




Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin Trial

Wed, 18 Oct 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - October 18, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that 14 qualified cancer clinics have requested to participate in its clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia ("AML").




Simple and Cost-effective Ways to Engage Patients Using eCOA and IRT Systems, New Webinar Hosted by Xtalks

Wed, 18 Oct 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - October 18, 2017) - This webinar will focus on how sponsors and CROs can use IRT and eCOA systems to promote patient engagement through features which reinforce compliance and retention, as well as functionality that allows for sharing information with patients throughout a clinical trial.




Critical Outcome Technologies Closes Second Tranche of $2 Million Private Placement

Wed, 18 Oct 2017 07:00:00 EDT

Funds to support continued clinical development of COTI-2 in head and neck squamous cell carcinoma




Building Smart Biomedical Devices Using Glass, Lasers, Sensors, and Chips - New Webinar Hosted by Xtalks

Wed, 18 Oct 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - October 18, 2017) - This webinar will explain how Glass Core Technology will lead customers to new products with a higher level of integration and more innovative features that result in smart biomedical devices and other emerging technologies. The live broadcast takes place on Friday, November 3, 2017 at 11am EDT (3pm GMT), with featured speaker Steve Groothuis, Chief Technology Officer for Samtec Microelectronics.




Freedom Leaf Inc Releases First Video From Green Market Europe In Spain; Notice On Filing (OTCQB: FRLF) Annual Report (10-K)

Wed, 18 Oct 2017 06:30:00 EDT

Pursuant to the Order for companies affected by Hurricane Irma all reports, schedules or forms must be filed on or before 10/19/17 SEE BELOW




Orgenesis to Present at BIO Investor Forum

Wed, 18 Oct 2017 06:00:00 EDT

GERMANTOWN, MD--(Marketwired - Oct 18, 2017) - Orgenesis Inc., (OTCQB: ORGS) ("Orgenesis " or "the Company"), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing, today announced that it will present at the BIO Investor Forum being held October 17-18, 2017 in San Francisco, CA.




The Journey from Passive to Active TMF with C.R. Bard, Inc. and Daiichi Sankyo, New Webinar Hosted by Xtalks

Tue, 17 Oct 2017 13:04:48 EDT

As the industry move to eTMF continues at a pace, hear from two organizations about their journeys to optimize clinical trial processes and the benefits they are seeing from making the shift to active TMF




The Hydropothecary Corporation Engages CFN Media to Develop New Investor Audience

Tue, 17 Oct 2017 09:30:00 EDT

SEATTLE, WA--(Marketwired - Oct 17, 2017) - CFN Media Group ("CFN Media", "CannabisFN"), the leading agency and digital media network dedicated to the North American cannabis industry, today announced that The Hydropothecary Corporation (TSX VENTURE: THCX) has engaged CFN Media to conduct a 3-month investor and market visibility program beginning on October 16th, 2017.




Dr. Martin Brenner Joins Recursion to Accelerate an Ambitious Plan to Industrialize Drug Discovery

Tue, 17 Oct 2017 09:00:00 EDT

The Industry Veteran Drug Hunter Brings more than a Decade of Experience to Recursion as Chief Scientific Officer




Abattis Offers a Solution to Canada's Cannabis Pesticide Problem -- CFN Media

Tue, 17 Oct 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Oct 17, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing Abattis Bioceuticals Corp. (CSE: ATT) (CNSX: ATT) (CNSX: ATT.CN) (OTCQB: ATTBF), whose wholly-owned subsidiary is one of the only publicly-traded third-party cannabis testing laboratories. A steady stream of cannabis recalls has prompted regulators in Canada to call for the mandatory testing of cannabis for unauthorized pesticides. With only a handful of third-party laboratories licensed to test cannabis, these service providers are becoming increasingly important.




Solis Tek, Inc. Enhances its Digital Lighting Product Offerings; Introduces Controller to Enable Commercial Growers to Take Complete Control of Lighting Environment

Tue, 17 Oct 2017 08:30:00 EDT

Controller Developed Specifically for the Lighting Conditions Required for Cannabis, Enables Growers to More Effectively Replicate the Sun's Light Cycles




Aphria Inc. Announces $80 Million Bought Deal

Tue, 17 Oct 2017 08:24:05 EDT

LEAMINGTON, ONTARIO--(Marketwired - Oct. 17, 2017) -




CannaRoyalty Commends Favourable CSA Notice Regarding Issuers with U.S. Marijuana-Related Activities

Tue, 17 Oct 2017 08:00:00 EDT

OTTAWA, ONTARIO--(Marketwired - Oct. 17, 2017) - CannaRoyalty Corp. (CSE:CRZ)(CSE:CRZ.CN)(CNSX:CRZ)(OTCQX:CNNRF) ("CannaRoyalty" or the "Company"), an active investor and operator in the legal cannabis industry, commented on Canadian Securities Administrators ("CSA") Staff Notice 51-352, Issuers with U.S. Marijuana-Related Activities (the "Notice").




Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

Tue, 17 Oct 2017 07:30:00 EDT

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors.




REPEAT - Cannabis Wheaton Provides Initial Advance of $5,000,000 to Beleave

Tue, 17 Oct 2017 07:30:00 EDT

VANCOUVER, BC--(Marketwired - October 17, 2017) - Cannabis Wheaton Income Corp. (TSX VENTURE: CBW) ("Cannabis Wheaton"or"CBW") and Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") are pleased to announce that, further to the news release dated October 5, 2017, CBW has provided an initial advance of $5,000,000 in non-dilutive debt financing by way of an instrument evidencing a debt obligation repayable in product equivalents (the "D.O.P.E. Note"). As previously announced, the proceeds of the D.O.P.E Note will be used by Beleave to fund the construction of an expansion facility, to be situated adjacent to Beleave's current facility outside of Hamilton, Ontario.




The Journey from Passive to Active TMF with C.R. Bard, Inc. and Daiichi Sankyo, New Webinar Hosted by Xtalks

Tue, 17 Oct 2017 07:30:00 EDT

As the industry move to eTMF continues at a pace, hear from two organizations about their journeys to optimize clinical trial processes and the benefits they are seeing from making the shift to active TMF




BioCorRx CEO Brady Granier Appears on MichaeLA on HLN to Discuss Alcohol Addiction

Tue, 17 Oct 2017 07:00:00 EDT

ANAHEIM, CA--(Marketwired - Oct 17, 2017) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, President & CEO of BioCorRx, appeared as a guest on MichaeLA hosted by Michaela Pereira live from CNN's Los Angeles bureau, to discuss alcohol addiction and the BioCorRx® Recovery Program, which works to help people suffering from alcohol and opioid abuse disorders. The segment can be viewed in the News & Media section of the BioCorRx website. To find out more information on the BioCorRx Recovery Program please visit www.beataddiction.com.




Ubiquitech Nine Month Revenue Up 44% From the Year Ago Period, Third Quarter 2017 Revenues Increase 25% From the Previous Year

Tue, 17 Oct 2017 07:00:00 EDT

DENVER, CO--(Marketwired - Oct 17, 2017) - Ubiquitech Software Corp. (OTC PINK: UBQU), through its operating subsidiary HempLifeToday.com, today announced its third quarter 2017 financial results. Revenues for the quarter increased to $1,134,310 from $906,352 during the prior year period, with earnings of $73,101 during the third quarter of 2017.




How Leveraging an Asia-Pacific Network Can Create Regional Efficiencies in Clinical Supply Management, New Webinar Hosted by Xtalks

Tue, 17 Oct 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - October 17, 2017) - The session will examine how to leverage the major clinical supply centers of China, Singapore and Japan to support clinical trials within the Asia-Pacific region for both local and global study sponsors, with featured speaker Daniel Gao, Site Director of Catalent's Clinical Supply Services in Shanghai. There will be two live broadcasts on Tuesday, October 31, 2017, at 10am EDT (2pm GMT/UK) and on Wednesday November 1, 2017, at 10am CST, 7:30am IST (11am JST and 1pm AEDT).




The Alliance for Regenerative Medicine Releases Agenda for Fifth Annual 2017 European Advanced Therapies Investor Day

Tue, 17 Oct 2017 04:00:00 EDT

LONDON, UNITED KINGDOM and WASHINGTON, DC--(Marketwired - Oct 17, 2017) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, along with co-hosts UK BioIndustry Association (BIA) and the Cell and Gene Therapy Catapult, releases the agenda for its annual European Advanced Therapies Investor Day, to be held November 9, 2017 in London.




Seventh Peer Reviewed Publication on Angle's Parsortix(TM) System

Tue, 17 Oct 2017 02:00:00 EDT

GUILDFORD, SURREY--(Marketwired - Oct 17, 2017) - Angle PLC (AIM: AGL) (OTCQX: ANPCY)




Cannabis Wheaton Provides Initial Advance of $5,000,000 to Beleave

Tue, 17 Oct 2017 00:01:00 EDT

VANCOUVER, BC--(Marketwired - October 17, 2017) - Cannabis Wheaton Income Corp. (TSX VENTURE: CBW) ("Cannabis Wheaton"or"CBW") and Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") are pleased to announce that, further to the news release dated October 5, 2017, CBW has provided an initial advance of $5,000,000 in non-dilutive debt financing by way of an instrument evidencing a debt obligation repayable in product equivalents (the "D.O.P.E. Note"). As previously announced, the proceeds of the D.O.P.E Note will be used by Beleave to fund the construction of an expansion facility, to be situated adjacent to Beleave's current facility outside of Hamilton, Ontario.




Vendor Oversight: Five Best Practices in Optimizing Limited Resources

Mon, 16 Oct 2017 10:00:00 EDT

TORONTO, ON--(Marketwired - October 16, 2017) - In an Xtalks clinical trials webinar upcoming on Wednesday, October 18, 2017 experts will share industry trends in optimizing internal resources, and five best practices to maximize productivity, manage time and budget, and achieve actionable, accurate clinical Intelligence when working with internal and external teams.




Athletes Free to Embrace CBD After WADA Decision - But There's a Catch -- CFN Media

Mon, 16 Oct 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Oct 16, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing the World Anti-Doping Agency's (WADA) recent decision to remove cannabidiol (CBD) from its list of banned substances in 2018, and that decision's ramifications for Medical Marijuana Inc.'s (OTC PINK: MJNA) subsidiary, HempMeds®.




The ALRT Diabetes Management System

Mon, 16 Oct 2017 08:30:00 EDT

Details of the patent pending diabetes management system featuring Predictive A1C and Insulin Dose Adjustment




Efficiently Managing Your Drug Supply Beyond IRT, New Webinar Hosted by Xtalks

Mon, 16 Oct 2017 08:22:47 EDT

TORONTO, ON--(Marketwired - October 16, 2017) - In a complimentary webinar taking place on Monday, October 30, 2017 at 1 p.m. EDT, industry expert Brett Castano, Senior Architect of Project Management at endpoint Clinical, will examine how sponsors can manage their clinical trails more efficiently.




Sirona Biochem to Present Kel-01 at Cosmetic 360 in Paris, France

Mon, 16 Oct 2017 08:00:00 EDT

VANCOUVER, BC--(Marketwired - October 16, 2017) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company") announced that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will attend and present on the trade floor at Cosmetic 360 in Paris, France on October 18-19, 2017. Cosmetic 360 is an international event that brings together the leading advancements in science with the largest, most influential cosmetics companies. In 2016, the conference hosted 200 exhibitors and was attended by over 4,000 delegates.




REPEAT - Cannabis Wheaton Announces Strategic Alliance With Large Convenience Store Group

Mon, 16 Oct 2017 07:30:00 EDT

VANCOUVER, BC--(Marketwired - October 16, 2017) - Cannabis Wheaton Income Corp. (TSX VENTURE: CBW) ("Cannabis Wheaton", "CW", or the "Company") is pleased to announce that it has entered an exclusive strategic alliance with the corporate owner of a national chain of convenience stores (the "Convenience Store Group") to develop and implement cannabis distribution and retail sale opportunities at all Convenience Store Group locations (collectively, the "Responsible Retailing Program").




Specific Cardiovascular issues in Oncology Drug Development, New Webinar Hosted by Xtalks

Mon, 16 Oct 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - October 16, 2017) - On October 24-25, 2017 scientific experts will be gathering at the CSRC/FDA Annual Meeting to discuss cardiac risk management and safety assessment in oncology drug development. BioTelemetry Research's Chief Medical Officer, Polina Voloshko, MD, and Vice President and Medical Director, Daniel Goodman, MD, will be attending. As a follow up to this meeting, Drs. Voloshko, and Goodman will be providing a complimentary webinar, broadcasting live on Wednesday, November 1, 2017 at 11:00am EDT, on the Key Takeaways from the upcoming CSRC/FDA Annual Meeting on Cardiac Safety and Cardiovascular Safety Issues in Oncology Drug Development.




Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

Mon, 16 Oct 2017 07:00:00 EDT

TORONTO, ONTARIO--(Marketwired - Oct. 16, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting "Cutaneous Lymphomas - Insights and Therapeutic Progress", October 13-15, in London, England.




Vitality Biopharma Announces Publication of International PCT Patent Filing for Cannabinoid Pharmaceuticals

Mon, 16 Oct 2017 07:00:00 EDT

Prodrug technology enables delivery of cannabinoids without psychoactivity for treatment of pediatric conditions




Realm Therapeutics to Present at the 2017 BIO Investor Forum

Mon, 16 Oct 2017 02:00:00 EDT

MALVERN, PA--(Marketwired - Oct 16, 2017) - Realm Therapeutics PLC (AIM: RLM)




Cannabis Wheaton Announces Strategic Alliance With Large Convenience Store Group

Mon, 16 Oct 2017 00:01:00 EDT

VANCOUVER, BC--(Marketwired - October 16, 2017) - Cannabis Wheaton Income Corp. (TSX VENTURE: CBW) ("Cannabis Wheaton", "CW", or the "Company") is pleased to announce that it has entered an exclusive strategic alliance with the corporate owner of a national chain of convenience stores (the "Convenience Store Group") to develop and implement cannabis distribution and retail sale opportunities at all Convenience Store Group locations (collectively, the "Responsible Retailing Program").